Q2 STOCKS TO BUY

Pharma Stock Upgraded on Eye Disorder Drug Sales

The brokerage bunch leans optimistic toward APLS

Deputy Editor
Oct 6, 2023 at 11:01 AM
facebook X logo linkedin


Apellis Pharmaceuticals Inc (NASDAQ:APLS) stock is enjoying a boost today after an upgrade from J.P. Morgan Securities to "overweight" from "neutral." The firm also lifted its price target to $81 from $60, expecting strong sales for the company's eye disorder drug, Syfovre.

Raymond James and Citigroup threw in a pair of bull notes as well, lifting their price targets to $92 and $70, respectively. Analysts were already leaning bullish on Apellis Pharmaceuticals stock. Of the 15 brokerages in coverage, 12 carry a "buy" or better rating, with three a tepid "hold."

Options bulls are chiming in on the note today, with calls running at double what's typically seen at this point. The January 2024 40 call is the most popular by far, followed by the October 45 call. It's also worth noting that short interest has been on the rise, now representing 13.5% of the stock's available float. 

At last glance, APLS was up 5.2% at $41.69, earlier as high as $43.31. Since the start of the year, the equity is down 20.1%. 

 

 

 

“Buy This Stock Now!” - Expert Who Called 11x On TSLA

He called a rare 11x on Tesla…

But now, thanks to Elon & Trump’s new alliance…

He says there’s a new opportunity that could be 1,000x BIGGER than Tesla – and it could completely revolutionize a $23 Trillion market.

It’s trading for less than $5 per share right now…

But it won’t be under the radar for long.

Discover The 1,000x Bigger Elon Opportunity Here